Emcure Pharmaceuticals Limited has disclosed pursuant to Regulation 30 of SEBI LODR Regulations that its subsidiary, Marcan Pharmaceuticals Inc., entered into share purchase agreements on July 2, 2026 (EDT) to acquire all Class E Special Shares in the share capital of Mantra Pharma Inc., a step-down subsidiary of the Company.

Transaction Details

  • Acquisition Date: July 2, 2026 (EDT)
  • Acquiring Entity: Marcan Pharmaceuticals Inc. (subsidiary of Emcure)
  • Target Entity: Mantra Pharma Inc. (step-down subsidiary of Emcure)
  • Shares Acquired: 100% of Class E Special Shares
  • Consideration: Cash payment of CAD $50 million aggregate
  • Completion Date: July 3, 2026
  • Post-Acquisition Status: Mantra continues to be 100% subsidiary of Marcan

Target Company Background

Mantra Pharma Inc. is incorporated under the laws of Quebec, Canada and was formed on November 6, 2023 through amalgamation of multiple entities including 9501-2969 Québec Inc., Mantra Pharma Inc. (erstwhile), Myriad Pharma Inc., Mantra Distribution Inc., Holding JFL Inc., Gestion Nirdac Inc., Gestion Stéphane Turcotte Inc., Gestion Beflan Inc., and Gestion Éléoraph Inc.

Business Operations: Marketing and distribution of prescription drugs and natural health products exclusively in the Canadian market.

Financial Performance:

  • FY2026: CAD $96.67 million turnover
  • FY2025: CAD $81.01 million turnover
  • FY2024: CAD $28.26 million turnover (for period November 6, 2023 to March 31, 2024)

Capital Structure: 1,000 Class A Common Shares and 24,000,000 Class E Special Shares without par value.

Regulatory Aspects

  • Related Party Status: The acquisition constitutes a related party transaction between two wholly-owned subsidiaries
  • Exemption: Qualifies for exemption under Regulation 23(5) of SEBI LODR Regulations
  • Arm's Length Basis: Transaction conducted at arm's length
  • Government Approvals: No specific government approvals required, subject to completion of requisite compliances under Canadian laws
  • Promoter Interest: No interest from promoter/promoter group/group companies except as step-down subsidiary of Emcure

Purpose and Impact

The acquisition fulfills the terms of Preferred Share Purchase Agreements entered into during the initial acquisition of Mantra. The transaction consolidates ownership of Mantra Pharma under Marcan Pharmaceuticals, maintaining Emcure's 100% indirect ownership through its subsidiary structure.

Disclosure Compliance

This intimation is made under Regulation 30 and Part A of Schedule III of SEBI LODR Regulations, provided within reasonable time considering time-zone differences. The disclosure references previous information contained in the company's prospectus filed during its Initial Public Offer.